Accord BioPharma's HERCESSI™ Achieves Preferred Formulary Status
HERCESSI™ has officially earned its place as one of two trastuzumab biosimilars with preferred status on Express Scripts' commercial formularies, allowing more patients to access affordable HER2-targeted oncology therapies. This change aims to enhance patient access to vital treatments for breast cancer and metastatic gastric cancers.
Significance of HERCESSI™'s Preferred Placement
This crucial formulary placement signifies a larger commitment to ensuring that cancer therapies remain accessible to patients in need. Accord BioPharma, under the umbrella of Intas Pharmaceuticals, is dedicated to developing therapies that not only address cancer needs but also expand treatment options for patients battling severe health conditions.
Express Scripts, recognized as one of the leading pharmacy benefit managers in the country, has indicated that HERCESSI™ will be included in its National Preferred Formulary beginning January 1, 2026. This move marks a significant breakthrough in the path toward more equitable healthcare for patients utilizing these critical therapies.
About HERCESSI™
HERCESSI™ is FDA-approved and specifically designed to treat HER2-overexpressing breast cancer, as well as metastatic gastric or gastroesophageal junction adenocarcinoma. As a biosimilar, it maintains no clinically meaningful differences from its reference product, HERCEPTIN® (trastuzumab). However, it does carry notable safety warnings, including risks for cardiomyopathy, infusion reactions, embryo-fetal toxicity, and pulmonary toxicity.
Patient Safety and Important Information
The introduction of HERCESSI™ also comes with the necessity for heightened vigilance regarding patient health. With its Boxed Warning, healthcare providers must monitor for signs of cardiomyopathy and other serious side effects. Patients are advised to seek immediate assistance if symptoms such as severe infusion reactions arise during treatment.
“Achieving preferred formulary status is a reaffirmation of the importance biosimilars hold in the healthcare landscape,” expressed Chrys Kokino, President and CEO of Accord U.S. “This decision ensures that patients gain unfettered access to necessary cancer treatments without undue financial burden.”
Future Plans and Market Access Strategy
The significance of this agreement goes beyond just one product; it’s part of a broader strategy to foster relationships with key payers to make oncology treatments more accessible. Accord BioPharma is keenly aware of the challenges patients face in affording effective healthcare solutions, and tactics include building partnerships that prioritize affordability in oncology.
How Copay Assistance Programs Work
For eligible patients, copay assistance services for HERCESSI™ will be available, creating mitigative strategies against the high costs commonly faced in cancer therapies. Patients seeking further information on these support services can access comprehensive details provided by Accord BioPharma.
Commitment to Quality Healthcare Solutions
Accord BioPharma is committed to enhancing the patient care process, providing not just effective therapies but also facilitating a seamless experience for those in treatment. Through its innovative approach to developing biosimilars, the company is focused on addressing both patient needs and healthcare system efficiencies.
In a relentless pursuit of quality and accessibility, Accord BioPharma aims to be at the forefront of the industry in supporting both patients and healthcare providers. By prioritizing affordability and access, it strives to impact the lives of those who need it most.
Frequently Asked Questions
What is HERCESSI™?
HERCESSI™ (trastuzumab-strf) is a biosimilar treatment for HER2-overexpressing breast cancer and gastric cancers, approved by the FDA.
Why is HERCESSI™ gaining preferred status?
This status enhances access, allowing patients to receive affordable treatments through leading pharmacy benefit managers like Express Scripts.
What safety concerns are associated with HERCESSI™?
HERCESSI™ carries Boxed Warnings for cardiomyopathy, infusion reactions, and risks during pregnancy, mandating careful monitoring by healthcare providers.
How does Accord BioPharma support patients using HERCESSI™?
Accord BioPharma offers copay assistance programs and strives to make the treatment process as smooth as possible for patients.
What is the future strategy of Accord BioPharma regarding market access?
The company aims to build meaningful partnerships with more pharmacy benefit managers, expanding access to its biologic treatments for patients across various health challenges.
